Iwasenko Jenna M, Scott Gillian M, Ziegler John B, Rawlinson William D
Virology Research, POWH and UNSW Research Laboratories, Prince of Wales Hospital, Randwick, NSW, Australia.
J Clin Virol. 2007 Oct;40(2):152-5. doi: 10.1016/j.jcv.2007.07.003. Epub 2007 Aug 14.
The emergence of human cytomegalovirus (CMV) antiviral resistance plays a significant role in disease progression in immunocompromised patients who have received antiviral therapy.
To determine the pattern of antiviral-resistant CMV strains in a highly immunocompromised child.
Retrospective specimens of blood and urine were analysed using PCR-sequencing to identify antiviral-resistant CMV strains containing UL97 or UL54 mutations.
CMV strains resistant to antiviral agents contributed to disease in a bone marrow transplant recipient with X-linked severe combined immunodeficiency (SCID) treated with ganciclovir (GCV) and foscarnet (FOS). Retrospective analyses detected GCV-resistant CMV (L595S) in a specimen taken after disease progression. This GCV-resistant CMV strain persisted for 1 year, after which time it was no longer detected even though the patient continued to receive GCV. A FOS-resistant strain (T700A) then emerged even though no FOS had been administered in the preceding year.
The detection of antiviral-resistant CMV did not follow the patterns found in other patients tested for antiviral resistance, including emergence of a FOS-resistant strain in the absence of antiviral-selective pressure. These findings indicate the patient's underlying immunosuppressive condition should be considered for diagnosis and management of resistant CMV.
人巨细胞病毒(CMV)抗病毒耐药性的出现,在接受抗病毒治疗的免疫功能低下患者的疾病进展中起着重要作用。
确定一名高度免疫功能低下儿童中抗病毒耐药CMV毒株的模式。
采用PCR测序分析血液和尿液的回顾性标本,以鉴定含有UL97或UL54突变的抗病毒耐药CMV毒株。
抗病毒药物耐药的CMV毒株导致一名接受更昔洛韦(GCV)和膦甲酸钠(FOS)治疗的患有X连锁重症联合免疫缺陷(SCID)的骨髓移植受者发病。回顾性分析在疾病进展后采集的一份标本中检测到耐GCV的CMV(L595S)。这种耐GCV的CMV毒株持续存在了1年,此后即使患者继续接受GCV治疗也未再检测到。尽管前一年未使用FOS,但随后出现了耐FOS毒株(T700A)。
抗病毒耐药CMV的检测未遵循在其他接受抗病毒耐药检测的患者中发现的模式,包括在没有抗病毒选择压力的情况下出现耐FOS毒株。这些发现表明,在诊断和管理耐药CMV时应考虑患者潜在的免疫抑制状况。